Study Design and Participants
nasopharyngeal necrosis, tumor, hemorrhages, Cancer
DISEASE PROGRESSION, TUMOR, HEMORRHAGES, ONCOLOGY, CANCER
This is an open-label, single-arm, phase II trial to assess the preliminary antitumor activity and safety of camrelizumab plus apatinib for patients with RM-NPC. The trial was approved by the Ethics Committee of the Sun Yat-sen University Cancer Center and registered on ClinicalTrials.gov (identifier: Patients with histologically confirmed NPC who were refractory to at least one line of systemic chemotherapy, or had disease progression within 6 months after induction, concurrent, or adjuvant chemoradiotherapy were enrolled. Other major eligibility criteria included age 18-70 years, recurrent NPC unsuitable for radiotherapy and surgery, an Eastern Cooperative Oncology Group performance status score of 0 or 1, and at least one measurable lesion. The main exclusion criteria included prior therapy with immunotherapy or any agents targeting VEGF(R), any factors affecting oral drug absorption, any grade ≥ 2 hemorrhages within 4 weeks, and tumor invasion to major vessels or obvious nasopharyngeal necrosis.